2024
Pícková, Markéta; Kahounová, Zuzana; Radaszkiewicz, Tomasz; Procházková, Jiřina; Fedr, Radek; Nosková, Michaela; Radaszkiewicz, Katarzyna Anna; Ovesná, Petra; Bryja, Vítězslav; Souček, Karel
Orthotopic model for the analysis of melanoma circulating tumor cells. Journal Article
In: Scientific reports, vol. 14, no. 1, pp. 7827, 2024, ISSN: 2045-2322, (Place: England).
Abstract | Links | BibTeX | Tags: *Melanoma/pathology, *Neoplastic Cells, *Skin Neoplasms/pathology, Animals, Circulating tumor cells, Circulating/pathology, Flow Cytometry, Humans, In vivo model, Lymphatic Metastasis, Melanoma, Metastasis, Tumorectomy
@article{pickova_orthotopic_2024,
title = {Orthotopic model for the analysis of melanoma circulating tumor cells.},
author = {Markéta Pícková and Zuzana Kahounová and Tomasz Radaszkiewicz and Jiřina Procházková and Radek Fedr and Michaela Nosková and Katarzyna Anna Radaszkiewicz and Petra Ovesná and Vítězslav Bryja and Karel Souček},
doi = {10.1038/s41598-024-58236-y},
issn = {2045-2322},
year = {2024},
date = {2024-04-01},
journal = {Scientific reports},
volume = {14},
number = {1},
pages = {7827},
abstract = {Metastatic melanoma, a highly lethal form of skin cancer, presents significant clinical challenges due to limited therapeutic options and high metastatic capacity. Recent studies have demonstrated that cancer dissemination can occur earlier, before the diagnosis of the primary tumor. The progress in understanding the kinetics of cancer dissemination is limited by the lack of animal models that accurately mimic disease progression. We have established a xenograft model of human melanoma that spontaneously metastasizes to lymph nodes and lungs. This model allows precise monitoring of melanoma progression and is suitable for the quantitative and qualitative analysis of circulating tumor cells (CTCs). We have validated a flow cytometry-based protocol for CTCs enumeration and isolation. We could demonstrate that (i) CTCs were detectable in the bloodstream from the fourth week after tumor initiation, coinciding with the lymph node metastases appearance, (ii) excision of the primary tumor accelerated the formation of metastases in lymph nodes and lungs as early as one-week post-surgery, accompanied by the increased numbers of CTCs, and (iii) CTCs change their surface protein signature. In summary, we present a model of human melanoma that can be effectively utilized for future drug efficacy studies.},
note = {Place: England},
keywords = {*Melanoma/pathology, *Neoplastic Cells, *Skin Neoplasms/pathology, Animals, Circulating tumor cells, Circulating/pathology, Flow Cytometry, Humans, In vivo model, Lymphatic Metastasis, Melanoma, Metastasis, Tumorectomy},
pubstate = {published},
tppubtype = {article}
}
Metastatic melanoma, a highly lethal form of skin cancer, presents significant clinical challenges due to limited therapeutic options and high metastatic capacity. Recent studies have demonstrated that cancer dissemination can occur earlier, before the diagnosis of the primary tumor. The progress in understanding the kinetics of cancer dissemination is limited by the lack of animal models that accurately mimic disease progression. We have established a xenograft model of human melanoma that spontaneously metastasizes to lymph nodes and lungs. This model allows precise monitoring of melanoma progression and is suitable for the quantitative and qualitative analysis of circulating tumor cells (CTCs). We have validated a flow cytometry-based protocol for CTCs enumeration and isolation. We could demonstrate that (i) CTCs were detectable in the bloodstream from the fourth week after tumor initiation, coinciding with the lymph node metastases appearance, (ii) excision of the primary tumor accelerated the formation of metastases in lymph nodes and lungs as early as one-week post-surgery, accompanied by the increased numbers of CTCs, and (iii) CTCs change their surface protein signature. In summary, we present a model of human melanoma that can be effectively utilized for future drug efficacy studies.
2023
Kahounová, Zuzana; Pícková, Markéta; Drápela, Stanislav; Bouchal, Jan; Szczyrbová, Eva; Navrátil, Jiří; Souček, Karel
Circulating tumor cell-derived preclinical models: current status and future perspectives. Journal Article
In: Cell death & disease, vol. 14, no. 8, pp. 530, 2023, ISSN: 2041-4889, (Place: England).
Abstract | Links | BibTeX | Tags: *Neoplastic Cells, Cell Culture Techniques, Circulating, Heterografts, Heterologous, Humans, Precision Medicine, Transplantation
@article{kahounova_circulating_2023,
title = {Circulating tumor cell-derived preclinical models: current status and future perspectives.},
author = {Zuzana Kahounová and Markéta Pícková and Stanislav Drápela and Jan Bouchal and Eva Szczyrbová and Jiří Navrátil and Karel Souček},
doi = {10.1038/s41419-023-06059-6},
issn = {2041-4889},
year = {2023},
date = {2023-08-01},
journal = {Cell death & disease},
volume = {14},
number = {8},
pages = {530},
abstract = {Despite the advancements made in the diagnosis and treatment of cancer, the stages associated with metastasis remain largely incurable and represent the primary cause of cancer-related deaths. The dissemination of cancer is facilitated by circulating tumor cells (CTCs), which originate from the primary tumor or metastatic sites and enter the bloodstream, subsequently spreading to distant parts of the body. CTCs have garnered significant attention in research due to their accessibility in peripheral blood, despite their low abundance. They are being extensively studied to gain a deeper understanding of the mechanisms underlying cancer dissemination and to identify effective therapeutic strategies for advanced stages of the disease. Therefore, substantial efforts have been directed towards establishing and characterizing relevant experimental models derived from CTCs, aiming to provide relevant tools for research. In this review, we provide an overview of recent progress in the establishment of preclinical CTC-derived models, such as CTC-derived xenografts (CDX) and cell cultures, which show promise for the study of CTCs. We discuss the advantages and limitations of these models and conclude by summarizing the potential future use of CTCs and CTC-derived models in cancer treatment decisions and their utility as precision medicine tools.},
note = {Place: England},
keywords = {*Neoplastic Cells, Cell Culture Techniques, Circulating, Heterografts, Heterologous, Humans, Precision Medicine, Transplantation},
pubstate = {published},
tppubtype = {article}
}
Despite the advancements made in the diagnosis and treatment of cancer, the stages associated with metastasis remain largely incurable and represent the primary cause of cancer-related deaths. The dissemination of cancer is facilitated by circulating tumor cells (CTCs), which originate from the primary tumor or metastatic sites and enter the bloodstream, subsequently spreading to distant parts of the body. CTCs have garnered significant attention in research due to their accessibility in peripheral blood, despite their low abundance. They are being extensively studied to gain a deeper understanding of the mechanisms underlying cancer dissemination and to identify effective therapeutic strategies for advanced stages of the disease. Therefore, substantial efforts have been directed towards establishing and characterizing relevant experimental models derived from CTCs, aiming to provide relevant tools for research. In this review, we provide an overview of recent progress in the establishment of preclinical CTC-derived models, such as CTC-derived xenografts (CDX) and cell cultures, which show promise for the study of CTCs. We discuss the advantages and limitations of these models and conclude by summarizing the potential future use of CTCs and CTC-derived models in cancer treatment decisions and their utility as precision medicine tools.